The protective effect of SGLT2i may be additive to that conferred by other drugs, such as RAS blockers, vitamin D analogs, or Glucagon-like peptide-1 receptor agonists (GLP1-RAs); other medications used for T2DM and CKD which mimic the effect of the natural hormone GLP1 in lowering serum glucose levels are also associated with anti-inflammatory and antioxidant properties [72]. This evidence concerns the gene GLP1R and chronic kidney disease.